Last reviewed · How we verify

Cabergoline (Dopamine Agonist) — Competitive Intelligence Brief

Cabergoline (Dopamine Agonist) (Cabergoline (Dopamine Agonist)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Endocrinology.

marketed Dopamine agonist Dopamine D2 receptor Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Cabergoline (Dopamine Agonist) (Cabergoline (Dopamine Agonist)) — University Hospital, Basel, Switzerland. Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cabergoline (Dopamine Agonist) TARGET Cabergoline (Dopamine Agonist) University Hospital, Basel, Switzerland marketed Dopamine agonist Dopamine D2 receptor
Lithium carbonate + perospirone hydrochloride Lithium carbonate + perospirone hydrochloride Shanghai Mental Health Center marketed Mood stabilizer + atypical antipsychotic combination Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone)
Risperidone and Ramelteon Risperidone and Ramelteon All India Institute of Medical Sciences, Bhubaneswar marketed Atypical antipsychotic + melatonin receptor agonist combination Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Flupentixole Flupentixole Technical University of Munich marketed Antipsychotic Dopamine D2 receptors
Quetiapine (drug) Quetiapine (drug) Medical University of Vienna marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor
Quetiapine 600mg Quetiapine 600mg AstraZeneca marketed atypical antipsychotic ["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
sodium valproate with Clozapine sodium valproate with Clozapine Shanghai Mental Health Center marketed Antipsychotic + mood stabilizer combination Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

  1. Sumitomo Pharma America, Inc. · 2 drugs in this class
  2. University Hospital, Toulouse · 2 drugs in this class
  3. Rennes University Hospital · 2 drugs in this class
  4. Britannia Pharmaceuticals Ltd. · 1 drug in this class
  5. Desitin Arzneimittel GmbH · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Intec Pharma Ltd. · 1 drug in this class
  8. Leiden University Medical Center · 1 drug in this class
  9. Ludwig-Maximilians - University of Munich · 1 drug in this class
  10. Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cabergoline (Dopamine Agonist) — Competitive Intelligence Brief. https://druglandscape.com/ci/cabergoline-dopamine-agonist. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: